Top 5 Cheap Stocks To Own For 2015

Top 5 Cheap Stocks To Own For 2015: CVS Corporation(CVS)

CVS Caremark Corporation operates as a pharmacy services company in the United States. The company?s Pharmacy Services segment provides a range of pharmacy benefit management services, including mail order pharmacy services, specialty pharmacy services, plan design and administration, formulary management, and claims processing; and drug benefits to eligible beneficiaries under the Federal Government?s Medicare Part D program. This segment primarily serves employers, insurance companies, unions, government employee groups, managed care organizations and other sponsors of health benefit plans, and individuals. As of December 31, 2010, it operated 44 retail specialty pharmacy stores, 18 specialty mail order pharmacies, and 4 mail service pharmacies located in 25 states, Puerto Rico, and the District of Columbia. This segment operates business under the CVS Caremark Pharmacy Services, Caremark, CVS Caremark, CarePlus CVS/pharmacy, CarePlus, RxAmerica, Accordant, and TheraCom names. The company?s Retail Pharmacy segment sells prescription drugs, over-the-counter drugs, beauty products and cosmetics, seasonal merchandise, greeting cards, and convenience foods through its pharmacy retail stores and online, as well as offers film and photo finishing, and health care services. This segment operated 7,182 retail drugstores located in 41 states, Puerto Rico, and the District of Columbia; and 560 retail health care clinics in 26 states and the District of Columbia under the MinuteClinic name. It has a strategic alliance with Alere, L.L.C. for the management of disease management program offerings that cover chronic diseases, such as asthma, diabetes, congestive heart failure, and coronary artery disease. CVS Caremark Corporation was founded in 1892 and is based in Woonsocket, Rhode Island.

Advisors' Opinion:

• [By Will Ashworth]

  CVS Caremark (CVS) delivered strong third-quarter earnings Tuesday morning that exce! eded expectations, and as a result, we got some raised fiscal 2013 guidance for CVS earnings.

• [By Charles Carlson]

  Steve Halpern: First, let's look at your conservative favorite of the past year, which was CVS Caremark (CVS), the pharmacy company. Could you tell us the reasoning behind your original recommendation and what's happened with the company over the past year.

• [By Chad Fraser]

  Big Moves Are Reshaping Baxter
  
  Baxter shares have risen 6.8% year-to-date, below the S&P 500s 7.6% gain. But even though the stock hasnt caused a lot of buzz with investors, management has made a number of important moves in the past two years.
  
  The first came in late 2012, when the company acquired Gambro AB for US$4.0 billion, marking the biggest acquisition in its 83-year history. Sweden-based Gambro makes dialysis products for patients with acute and chronic kidney disease. The company is the worlds second-largest manufacturer of dialysis machines, after Germanys Fresenius.
  
  Baxter already had a presence in the dialysis market but mainly focused on in-home equipment, while Gambros products are mostly used in clinics.
  
  This is a large and growing market for the company: according to the Baxter, approximately two million people worldwide are on some form of dialysis, and that number is growing by more than 5% annually due to ri sing rates of diabetes and hypertension.
  
  Another major move came in March, when Baxter announced that it would break itself into two separate firms along the lines of its current divisions; it aims to complete the split in mid-2015.
  
  The breakup makes sense because the two units have separate profiles, with the medical devices business being more defensive, while the biopharmaceuticals unit grows faster, albeit with greater risk, wrote Springer.
  
  One of those risks is rising competition. For example, Biogen Idecs (NasdaqGS: BIIB) Eloctate hemophilia A therapy received FDA approval in June. Eloc! tate coul! d become a significant competitor to Baxters Advate treatment, which controls about 35% of the market. But Advate has the advantage of being well established: it was approved more than a decade ago and is now used in 64 countries.
  
  Eloctate is expected to cost roughly the same as Advate, but it requires fewer injections. Baxter is currently developing a longer-

• [By Tabitha Jean Naylor]

  Two of the most prolific leaders in the drugstore space are CVS Caremark (NYSE: CVS) and Walgreen Co. (NYSE: WAG). From a distance, these two powerhouses are neck-and-neck in the stock game, but upon closer examination one may actually be a better overall fit for an investment portfolio.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-5-cheap-stocks-to-own-for-2015.html